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Reversal of Murine Epidermal Atrophy by Topical
Modulation of Calcium Signaling
Basile Darbellay1, Laurent Barnes1, Wolf-Henning Boehncke1, Jean-Hilaire Saurat2 and Gu¨rkan Kaya1
Cytosolic Ca2þ signals are performed by Ca2þ releases from the endoplasmic reticulum and Ca2þ influx from
the extracellular medium. Releases rely on the refilling of the intracellular Ca2þ stores by the Ca2þ influx
‘‘Store-Operated Calcium Entry’’ (SOCE) via the channel Orai1. Here we show that Orai1 expression, SOCE
amplitude, and epidermal proliferation are decreased in the epidermis of patients with skin fragility when
compared with aged nonatrophic skin. Epidermal atrophy was induced in mice by the inhibition of Orai1 with
small interfering RNA and the topical application of a SOCE blocker BTP2. The inhibition of Orai1 impaired the
heparin-binding epidermal growth factor (HB-EGF)-induced Ca2þ influxes and fully prevented the mitogen
effect of HB-EGF in primary human keratinocytes. Importantly, epidermal proliferation correlated with Orai1
expression in mice. Conversely, the topical application of an Orai1 activator, the benzohydroquinone (BHQ),
increased the epidermal thickness and proliferation, whereas the pro-proliferative effect of BHQ was
prevented by the inhibition of Orai1. Finally, the topical application of BHQ reversed the epidermal atrophy
induced by corticosteroids in mice. The topical modulation of Ca2þ signals may thus be a promising
therapeutic strategy in dermatology.
Journal of Investigative Dermatology (2014) 134, 1599–1608; doi:10.1038/jid.2013.524; published online 2 January 2014
INTRODUCTION
Human epidermal atrophy is observed in chronic cutaneous
insufficiency/fragility, a clinical syndrome characterized by
the dermo–epidermal atrophy of the skin caused by aging,
chronic UV exposure, or long-term corticosteroid use (Kaya
and Saurat, 2007; Kaya et al., 2008). The prevalence of skin
fragility is around 32% in individuals aged over 60 years
(Mengeaud et al., 2012).
Epidermal homeostasis is regulated by the balance between
the proliferation of basal keratinocytes and the differentiation
of suprabasal keratinocytes. In a murine model of epidermal
atrophy, it has been shown that proliferation is impaired,
whereas differentiation occurs normally (Kaya et al., 2006;
Pastore et al., 2008). Ca2þ signals are known to control
keratinocyte differentiation, but it is poorly understood
whether Ca2þ signals also control keratinocyte proliferation
(Hennings et al., 1980; Sharpe et al., 1989; Yuspa et al., 1989;
Tang and Ziboh, 1991; Tu et al., 1999; Numaga-Tomita and
Putney, 2012).
It has been shown that the stimulation of EGFR activates the
phosphoinositol 3-kinase pathways (Rodrigues et al., 2000; Li
et al., 2001) and triggers cytosolic Ca2þ signals that control
cell proliferation (Moolenaar et al., 1986; Cheyette and Gross,
1991; Sanchez-Gonzalez et al., 2010; Tajeddine and Gailly,
2012; Leroy et al., 2013). Accordingly, several epidermal
mitogens, including epidermal growth factor (EGF), elicit
Ca2þ signals, which are fully inhibited in keratinocytes with
depleted intracellular Ca2þ stores (Watt et al., 1991; Sharpe
et al., 1993; McGovern et al., 1995; Hoq et al., 2011). These
results strongly suggest that Ca2þ releases from the
endoplasmic reticulum, the principal intracellular Ca2þ
store, are involved in the control of keratinocyte proliferation.
As the Ca2þ content of the endoplasmic reticulum is
limited, Ca2þ releases rely on the refilling of the stores
through a Ca2þ influx from the extracellular medium, which
is named Store-Operated Calcium Entry (SOCE) (Putney,
1986; Li et al., 1997; Hofer et al., 1998a, 1998b; Parekh
and Putney, 2005). SOCE silently refills the Ca2þ stores and is
inactivated when stores are full (Jousset et al., 2007; Darbellay
et al., 2009, 2010, 2011; Shen et al., 2011). The plasma
membrane Ca2þ channel Orai1 is the main molecular partner
of SOCE (Feske et al., 2006; Vig et al., 2006; Zhang et al.,
2006). Orai1 is activated by STIM1, the Ca2þ sensor of the
endoplasmic reticulum (Liou et al., 2005; Roos et al., 2005;
Wang et al., 2009; Zhou et al., 2009). The inhibition of the
sarco/endoplasmic Ca2þ ATPase with thapsigargin (Tg) or
benzohydroquinone (BHQ) activates Orai1. As Orai1-
knockout mice present with epidermal atrophy (Gwack
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et al., 2008) and the cutaneous phenotype of Orai1-deficient
patients has not been studied yet (Byun et al., 2010; Feske
et al., 2010; Chang et al., 2012), the role of Orai1 in the
epidermis and epidermal atrophy has to be clarified.
Interestingly, Orai1 polymorphism may be associated with
susceptibility to atopic dermatitis (Chang et al., 2012).
RESULTS
Orai1 expression and SOCE amplitude are decreased in the
epidermis of patients with epidermal atrophy
In healthy human skin, Orai1 was detected throughout the
epidermis, and the level of expression of Orai1 was higher in
the basal layer than in the suprabasal layers (Figure 1a, upper
panel, a¼basal layer, b¼ suprabasal layers). The skin of
patients with skin fragility is characterized by epidermal
thinning and linearization, which is due to the loss of rete
ridges (Figure 1b, upper panel; Kaya and Saurat, 2007).
Interestingly, the gradient of Orai1 expression that is
observed in healthy aged epidermis was lost in atrophic
skin, and the expression of Orai1 was markedly reduced
(Figure 1a and b, upper panel). In control epidermis, measure-
ments of the intensity of Orai1 staining revealed that Orai1
expression is 48±7% lower in the suprabasal layers than in
the basal layer (Figure 1c). In epidermal atrophy, signal
quantification showed a decreased Orai1 expression of
62±5% in the basal layer and 29±3% in suprabasal layers,
when compared with healthy aged skin of the same average
age (Figure 1c and Supplementary Data S1 online). Thus,
Orai1 expression is markedly decreased in the basal layer of
atrophic epidermis.
Epidermal proliferation has been shown to be slightly
decreased in healthy aged skin compared with young healthy
skin (Giangreco et al., 2010). In epidermal atrophy, the
number of cells positive for the proliferation marker Ki67
was markedly decreased when compared with aged healthy
skin (Figure 1a and b, lower panel). The determined average
frequency of Ki67-positive nuclei was 4±3 nuclei per 2 mm
and 16±4 nuclei per 2 mm in atrophic and control skin,
respectively (Figure 1d). Thus, epidermal proliferation is
impaired in epidermal atrophy, whereas epidermal differentia-
tion occurs normally (Supplementary Data S2 online).
As Orai1 is known to control SOCE, we then explored the
amplitude of Tg-induced SOCE in keratinocytes isolated from
healthy and atrophic skin by using the fluorescent cytosolic
Ca2þ indicator Fura-2. For this purpose, we isolated primary
human keratinocytes (PHKs) from unused surgical specimens.
As shown in Figure 1e, the resting cytosolic Ca2þ levels and
the amount of Ca2þ released from intracellular stores by Tg
Control
O
ra
i1
Ki
67
Atrophy
B
A
B
A
M
ea
n 
st
ai
ni
ng
 in
te
ns
ity
(no
rm
a
liz
e
d)
Ki
67
-p
os
itiv
e
 n
u
cl
ei
Pe
a
k 
SO
CE
34
0 
nm
/3
80
 n
m
A B A B
0 4 8 12
Time (min)
Control Co
ntr
ol
Co
ntr
ol
Atrophy
Atr
op
hy
Atr
op
hyn =5 Patients/condition
n=5 Patients/
condition
n = 5 Patients/
condition
P =10–6
P =10–6
P =10–4
Primary human keratinocytes
Keratinocytes from atrophic skin
0
5
10
15
20
25
n =16 cells
Ca2+
250 nM
Ca2+
1.8 mM
Tg 2 µM
n =12 cells
0
1
0.75
0.25
0.5
1.2
0.8
0.6
0.4
0.2
0
1
a
c d e f
b
1.2
0.8
0.6
0.4
0.2
0
1
Figure 1. Store-Operated Calcium Entry (SOCE) is compromised in epidermal atrophy. Histological sections of healthy human skin (a) and atrophic skin
(b) stained for Orai1 and Ki67; A¼ basal layer, B¼ suprabasal layers. (c) Quantification of Orai1 expression determined by the intensity of staining in
a and b (mean±SD, see Materials and Methods). (d) Quantification of the Ki67-positive nuclei per 2 mm of the dermo–epidermal junction (mean±SD,
see Materials and Methods). (e) Cytoplasmic Ca2þ assessed by Fura-2 probe 24 hours after isolation of primary keratinocytes. Intracellular Ca2þ stores were
depleted using 2mM thapsigargin (Tg) in a medium containing 250 nM Ca2þ , and, subsequently, 1.8 mM Ca2þ was added to the external medium to reveal
SOCE (one representative experiment). (f) Peak Tg-induced SOCE amplitude measured in five patients/condition (mean±SD). Bar¼ 150mm.
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(1mM) are similar in healthy and atrophic skin. However, the
amplitude of SOCE, which is activated by the depletion of
Ca2þ stores and measured after the addition of 1.8 mM Ca2þ
to Tg-treated cells, is decreased by 68±10% in epidermal
atrophy (Figure 1e and f). Considered together, these results
suggest that SOCE function is compromised because of a
reduced Orai1 expression in atrophic epidermis.
Inhibition of Orai1 induces skin atrophy and decreases
epidermal proliferation in mice
To test whether the decrease of Orai1 expression observed in
skin fragility may cause epidermal atrophy, we decided to
inhibit Orai1 in the epidermis of mice. To this end, we first
applied small interfering RNA (siRNA)-targeting Orai1
(siOrai1) and control siRNA on the skin of mice, as described
in Materials and Methods. The effect of the topical application
of siOrai1 on the epidermal expression of Orai1 was assessed
by Orai1 immunostaining on histological sections. As shown
in Figure 2a, the expression of Orai1 in the epidermis was
decreased by 63±16%, whereas the dermal expression of
Orai1 was stable when compared with control mice
(Figure 2a, upper panel and Supplementary Data S3 online).
Importantly, the epidermal thickness was reduced by
72±19% in Orai1-silenced epidermis (Figure 2a). We then
assessed epidermal proliferation by counting Ki67-positive
nuclei. In Orai1-silenced epidermis, the number of Ki67-
positive cells was decreased by 77±12% when compared
with control (Figure 2a, lower panel, control 56±16, siOrai1
13±3 Ki67-positive nuclei per 2 mm). We then explored the
effect of the topical application of BTP2, an inhibitor of Orai1
(Bogeski et al., 2010), on the thickness and proliferation of the
mouse epidermis. Epidermal thickness was markedly reduced
by 50±15% in mice treated with a total dose of 0.45mg cm 2
of BTP2 applied over 2 weeks, twice a day, when compared
with mice treated with excipient only (Figure 2b, upper panel).
Ki67 was reduced by 77±6% in mice treated with BTP2
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Figure 2. Orai1 inhibition results in epidermal atrophy in mice. (a) Histological sections of mouse skin stained for Orai1, hematoxylin–eosin (HE), and Ki67
(left panel, E¼ epidermis, D¼ dermis). Quantification of Orai1 staining intensity, epidermal thickness, and Ki67-positive nuclei standardized to control
(right panel, mean±SD). Mice were treated with topical small interfering RNA (siRNA) (2 per day, 2 weeks, see Materials and Methods). (b) Histological
sections of mouse skin stained with HE and for Ki67 (left panel). Quantification of epidermal thickness standardized to control and Ki67-positive nuclei
(right panel, mean±SD). Mice were treated with topical BTP2 (2 per day, 2 weeks). (c) Ki67-positive nuclei per field at  40 plotted with the level of expression
of Orai1 (mean staining value per field at 40) in mice treated with siRNA. Ki67 and Orai1 expressions are normalized. Bar¼150mm.
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(Figure 2b, lower panel). These results show that the inhibition
of Orai1 induces epidermal atrophy and impedes epidermal
proliferation in mice. However, the method used to perform
the knockdown of Orai1 resulted in an inhomogeneous
silencing of Orai1. We thus decided to plot the Ki67 as a
function of the level of expression of Orai1 assessed by
immunostaining (three mice in each condition, 10 fields at
 40). Figure 2c shows that the Ki67 positivity varied as
a sigmoidal function of the expression of Orai1. These
results show that Orai1 controls the epidermal thickness and
proliferation in mice in vivo.
Heparin-binding EGF-induced proliferation of human
keratinocyte depends on Orai1
The results summarized in Figure 2 suggest that Ca2þ
signaling via Orai1 controls epidermal proliferation in mice.
To further test this hypothesis, we evaluated the global Ca2þ
entries induced by heparin-binding (HB)-EGF in PHKs by
assessing the Mn2þ quench of Fura-2. Mn2þ enters the cells
through Ca2þ channels and quenches Fura-2 fluorescence so
that the Fura-2 emission at 360 nm is directly linked to Ca2þ
influxes. As shown in Figure 3a and b, Fura-2 emission at
360 nm was decreased on HB-EGF stimulation, indicating that
an influx of Ca2þ has been activated. Treatment with BTP2
and knockdown of Orai1 with siRNA decreased the maximum
slope of the Fura-2 quench by 90±4 and 91±6%, respec-
tively (Figure 3a and b). Supplementary Data S4 online show
that Orai1 expression was decreased by 85±3% in PHKs
treated with anti-Orai1 siRNA.
We then explored whether the potent pro-proliferative effect
of HB-EGF in keratinocytes depended on Orai1. For this
purpose, we assessed the effect of Orai1 silencing and BTP2
on the HB-EGF-induced proliferation of PHKs. Compared with
the proliferation in a medium without HB-EGF, the number of
keratinocytes was increased by a factor of 2.966±0.09% after
4 days of culture in HB-EGF-supplemented medium
(Figure 3c). In keratinocytes cultured in a medium supple-
mented with BTP2 (1mM) and HB-EGF, the number of cells
was similar to the number in the absence of HB-EGF
(Figure 3c). Similarly, Orai1 silencing resulted in a cell number
in the presence of HB-EGF that is not significantly different
from that obtained in its absence (Figure 3c). We conclude
from the results of Figure 3 that the mitogenic effect of HB-EGF
depends on Ca2þ influxes that are supported by Orai1.
BHQ-induced Ca2þ influx through Orai1 elicits epidermal
hyperplasia in mice and stimulates human keratinocyte
proliferation
Our results show that SOCE function is impaired in the
atrophic epidermis of patients with skin fragility (Figure 1)
and that the inhibition of Orai1 results in epidermal atrophy in
mice (Figure 2). In addition, Ca2þ influxes supported by Orai1
are required during HB-EGF-induced keratinocyte prolifera-
tion in PHKs (Figure 3). We then explored whether artificial
activation of Orai1 could be sufficient to trigger keratinocyte
proliferation and induce epidermal hyperplasia. To induce a
Ca2þ influx through Orai1, we used the sarco/endoplasmic
Ca2þ ATPase inhibitor BHQ, which causes passive Ca2þ
releases from the endoplasmic reticulum and thus activates
Orai1. Figure 4a shows that BHQ (20mM) induced Ca2þ
influxes in PHKs, as indicated by the immediate decrease of
the Fura-2 emission at 360 nm after BHQ addition in a
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Figure 3. HB-EGF-induced proliferation relies on Orai1 in primary human
keratinocytes (PHKs). Fura-2 fluorescence at 360-nm excitation measured in
PHKs: (a) experiment was performed 2 days after transfection with siRNA;
(b) BTP2 was applied 10 minutes before the addition of Mn2þ (left panels: one
representative experiment, right panels: normalized mean±SD in three
independent experiments). (c) Proliferation of PHKs assessed by cell counting
(see Methods). HB-EGF 5 ng ml1 and BTP2 1mM were added in the culture
medium. Day 0 is 48 hours after small interfering RNA (siRNA) transfection
(mean±SD in 10 fields/condition in three independent experiments).
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medium containing 0.1 mM Mn2þ . Orai1 silencing with
siRNA and BTP2 (1mM) inhibited BHQ-induced Ca2þ influxes
in PHKs, as they decreased the slope of the Fura-2 quench
traces by 88±6 and 85±3%, respectively (Figure 4a and b).
Results of Figure 4a suggest that BHQ could promote
keratinocyte proliferation by mimicking the HB-EGF-
induced Ca2þ influx through Orai1. Therefore, we mea-
sured the effect of BHQ (20 mM) on the proliferation of PHKs.
Keratinocytes were exposed to BHQ for 45 minutes twice a
day during 4 days. Figure 4c shows that BHQ increased the
rate of proliferation, measured by the number of cells, in
HB-EGF-free medium to 95±4% of the maximum pro-
liferation induced by HB-EGF. The effect of BHQ
depended on Orai1, as Orai1 silencing and BTP2 (1 mM)
fully prevented the pro-proliferative effect of BHQ in human
keratinocytes (Figure 4c). These results show that BHQ
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stimulates human keratinocyte proliferation through Ca2þ
influx supported by Orai1.
Finally, we explored whether the topical application of
SOCE activators increases epidermal thickness and prolifera-
tion in mice in vivo. Former results have shown that the
topical application of Tg induces an epidermal hyperplasia
within 48 hours of treatment in mice (Hakii et al., 1986;
Harmon et al., 1996). However, Tg has the inconvenience of
irreversibly blocking the sarco/endoplasmic Ca2þ ATPase,
and this may have toxic and protumoral effects. BHQ,
however, has only transient inhibitory effects on the sarco/
endoplasmic Ca2þ ATPase (Supplementary Data S5 online).
Figure 4d and Supplementary Data S6 show that BHQ elicits
Ca2þ influxes that are fully blocked by BTP2 and Orai1
silencing in murine primary keratinocytes. Supplementary
Data S4 online show that Orai1 expression was decreased
by 80±4% in murine primary keratinocytes treated with anti-
Orai1 siRNA. After a total dose of 3mg cm2 of BHQ (20mM)
applied on the interscapular region of mice twice a day for 2
weeks, BHQ increased the epidermal thickness by a factor of
2.61±0.32 (Figure 4d). Measurements of epidermal prolifera-
tion using Ki67 immunostaining revealed 48±10 Ki67-posi-
tive nuclei per 2 mm in control mice and 121±23 in BHQ-
treated mice (Figure 4d). Figure 4d also shows that the
epidermal proliferation and hyperplasia induced by BHQ is
prevented by BTP2 (1mM). Importantly, Supplementary Data
S7 online show that the topical application of BHQ (20mM)
twice a day for 48 hours on the back of hairless mice increases
epidermal proliferation but not epidermal thickness, and thus
the increase in proliferation preceded the increase in thick-
ness. Together, Figure 4 shows that Orai1 promotes human
keratinocyte proliferation in vitro and that the topical applica-
tion of the Orai1 activator BHQ induced epidermal hyperpla-
sia in mice.
Corticosteroid-induced skin atrophy is reversed by topical
application of BHQ in mice
To test the effect of topical application of Orai1 modulators on
corticosteroid-induced skin atrophy, we first induced skin
atrophy with the topical application of clobetasol propionate
(CP, 0.05%) twice a day for 10 days in SKH1 hairless mice
(Figure 5a). Epidermal thickness was reduced by 79±9% and
the number of Ki67-positive nuclei was decreased by 82±9%
in CP-treated mice (Figure 5a and b). Supplementary Data S8
show that these values are not significantly different from the
atrophy and Ki67 positivity measured in the murine epidermis
of one littermate per independent experiment (n¼ 3 mice)
following 5 days of treatment with CP 0.05% twice a day.
Thus, at the time the co-application of BHQ and CP was
started, the epidermal atrophy was completely installed. From
the 6th day, BHQ (20mM) was applied twice a day for 5 days
together with CP. In mice treated with CPþBHQ, epidermal
thickness and the number of Ki67-positive nuclei per 2 mm
were increased, respectively, by 169±44 and 197±52%
compared with control. Importantly, treatment with CP did
not modify the level of expression of Orai1 (Supplementary
Data S10). These results show that the topical application of
SOCE modulators is efficient to reverse CP-induced epidermal
atrophy in mice.
DISCUSSION
All in all, our results underline the potential of topical SOCE
activators for reversing the corticosteroid-induced epidermal
atrophy. In addition, our results highlight the key role of SOCE
in the regulation of keratinocyte proliferation in murine
epidermis.
In patients with skin fragility, and thus with a severe
epidermal atrophy, we show that the epidermal expression
of Orai1 and the amplitude of SOCE were markedly decreased
(Figure 1). As a reduced proliferation without any differentia-
tion defects is the hallmark of skin fragility, our results suggest
that Orai1 could control keratinocyte proliferation in vivo
(Kaya et al., 2006). Accordingly, we found that the chemical
and the genetic inhibition of Orai1 decreased epidermal
proliferation without affecting differentiation in mice
(Figure 2 and Supplementary Data S9). Thus, our results may
explain the already reported epidermal atrophy in Orai1-
knockout mice (Gwack et al., 2008). We then showed that
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Orai1 also controls the proliferation of PHKs in vitro (Figure 3).
Therefore, our results demonstrate a crucial role of SOCE in
the regulation of epidermal homeostasis and suggest that
impaired SOCE could be involved in the etiology of epidermal
atrophy in skin fragility. As the epidermis of patients present-
ing SOCE mutations has not been described to date, this
remains an interesting point to be clarified in the future.
It is well known that cytosolic Ca2þ signals promote the
differentiation of keratinocytes. This may appear in contra-
diction with our results, which show that Ca2þ influx through
Orai1 promotes keratinocyte proliferation. These findings are
not discrepant, however, as cytosolic Ca2þ signals control
distinct cell activities depending on the subcellular location,
frequency, amplitude, and duration of the Ca2þ transient
(Berridge, 2001). Accordingly, growth and differentiation
stimuli were shown to induce different Ca2þ signals in
keratinocytes (Sharpe et al., 1993). Furthermore, several pro-
proliferative molecules were shown to induce cytosolic Ca2þ
transients in keratinocytes (Hakii et al., 1986; Pillai et al.,
1990; Watt et al., 1991; Pillai and Bikle, 1992; Tuschil et al.,
1992; Sharpe et al., 1993; McGovern et al., 1995; Harmon
et al., 1996; Lowry et al., 1996; Lee et al., 2001; Yano et al.,
2003, 2004; Meyer-Hoffert et al., 2004; Hoq et al., 2011).
Importantly, both Orai1 and STIM1 were shown to promote
both proliferation and differentiation of HaCat keratinocytes
(Numaga-Tomita and Putney, 2012). These former studies
clearly show that cytosolic Ca2þ signals neither necessarily
prevented keratinocyte proliferation nor systematically
induced their differentiation. Subsequently, we show that
epidermal differentiation is normal in atrophic epidermis
(where Orai1 expression is severely decreased) and in
Orai1-inhibited murine epidermis (Supplementary Data S2
and S9 online). We then assume that Orai1 may be involved
in pro-proliferative Ca2þ signals rather than in the Ca2þ
signaling of differentiation. As several Ca2þ channels were
shown to control keratinocyte differentiation, it is not surpris-
ing that a defect of Orai1 is insufficient to severely impair
epidermal differentiation in vivo (Cai et al., 2006; Muller
et al., 2008; Lehen’kyi et al., 2011; Leuner et al., 2011).
Finally, our results highlight the promising therapeutic
potential of the topical modulation of cytosolic Ca2þ signaling
in dermatology. For example, corticosteroids are widely used
as anti-inflammatory drugs in general medical practice,
whereas their atrophogenic side effects frequently limit their
topical or systemic use. Our results suggest that the topical
application of SOCE modulators could be a relevant option for
preventing or reversing the corticosteroid-induced epidermal
atrophy (Kaya et al., 2006; Barnes et al., 2012).
MATERIALS AND METHODS
Keratinocyte isolation and treatments
Skin samples, cell dissociation, and culture from keratinocytes were
prepared as follows. Skin samples were desepidermized with thermo-
lysin, and then keratinocytes were isolated with trypsin. The suspen-
sion was centrifuged and resuspended in a wash medium to remove
cutaneous debris (Ham’s F10 with 15% fetal calf serum). Finally, cells
were seeded on dishes coated with collagen IV. Human skin samples
were obtained from unused surgical specimen from 12 patients: 6
healthy (81, 81, 82, 74, 89, and 86) and 6 suffering from skin fragility
(92, 86, 75, 77, 87, and 82). The mean age of healthy patients (82±5,
mean±SD) and patients with skin fragility (83±6, mean±SD) was
not significantly different. Healthy patients were defined by the
normal aspect of the skin clinically and the absence of alterations
on microscopic examination. Patients suffering from skin fragility
were defined on clinical criteria confirmed by histological character-
ization. All samples were collected from the upper chest. The patients
reported no particular history of overexposition to the sun or to
systemic or topical steroids. Signs of sun-damaged skin (deep
wrinkles, inhomogeneous pigmentation, actinic lesions, and elastosis)
were not detected. Elastic fiber staining excluded excessive UV
exposure in our samples. On these bases, cutaneous insufficiency
was attributed to aging. The primary diagnoses are as follows: for
healthy skin, 2 basal cell carcinomas, 3 cutaneous lymphomas, and 1
metastasis; for atrophic skin, 2 basal cell carcinomas, 2 cutaneous
lymphomas, and 2 metastases. PHKs (Invitrogen C-020-5C, Carlsbad,
CA) were cultured in normal keratinocyte serum free medium
(Invitrogen) supplemented with bovine pituitary extract and EGF
(5 ng ml 1), or in a medium lacking EGF supplemented with bovine
pituitary extract only. Clobetasol was purchased from Sigma-Aldrich
(St Louis, MO). Experiments on human tissue have been performed
according to the authorization CER12-091 of the Human Ethical
Commission, University Hospital, Geneva. The study was conducted
according to the Declaration of Helsinki Principles. Written informed
consent was provided by all patients.
Immunohistochemical staining
Skin sections from mouse and human skins were either cryo-
conserved by including in OCT (Sakura Finetek Europe, Alphen aan
den Rijn, The Netherlands) or dehydrated and embedded in paraffin.
Ki67 and Orai1 immunostainings were performed on paraffin-
embedded sections. Sections were rehydrated, antigens were
unmasked by boiling sections in 10 mM citrate buffer or 1 nM EDTA,
and then stained with their respective antibodies (M7249, clone TEC-3,
anti-Ki67 antibody from DAKO, Glostrup, Denmark; anti-Orai1 anti-
body from Sigma, 08264, Carlsbad, CA). An anti-rat biotinylated anti-
body was used as secondary antibody to detect Ki67. An anti-rabbit
biotinylated antibody was used as secondary antibody to detect Orai1.
Sections were then incubated with a ready-to-use streptavidin-HRP
solution (DAKO) and revealed with 3,39-diaminobenzidine (Sigma).
Images were acquired with a bright-field and epifluorescence
microscope (Avio vert 200, AxioCam HRc, Carl Zeiss, Oberkochen,
Germany). The number of Ki67-positive nuclei per 2 mm of dermo–
epidermal junction is shown in bar graphs in all figures. Bar¼ 150mm
in all figures. To avoid irrelevant variations of the staining intensity in
the immunohistochemistry, all conditions were stained with the same
solutions and timing within each independent experiment. Basal and
suprabasal layers were selected manually to compare the intensity of
Orai1 staining. Supplementary Data S4 online show that the anti-
Orai1 antibody from Sigma (08264) detects bands of the same size in
humans and mice.
Mouse treatments
SKH1 hairless mice (1.5–4 months old) were treated by a topical
application (100ml) of CP 0.05%, BTP2 1mM, or BHQ 20mM dissolved
in ethanol solvent. Solvent (control), CP 0.05%, BTP2, cyclopiazonic
acid, BHQ, and siRNA were applied in the morning and the evening
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(6–8 hours apart) every day for the duration indicated in the figure
legends. For in vivo transfection of siRNA, a solution containing
250ml of Opti-MEM, 3ml of Lipofectamine RNAiMax (Invitrogen), and
75 pmol of siRNA (Invitrogen) was deposited on a surface of 1 cm2 on
the upper back of hairless mice following 10 tape-strippings of the
treated zone. The mix was maintained under occlusion for 5 minutes.
At 48 hours before sampling, tape stripping was stopped, but treat-
ment with the solution of transfection was continued twice a day. The
siRNAs used were SiOrai1 (50-GCCGGGUAUCUCUGCGGCGtt-30)
and control siRNA (4390843 Invitrogen). Mice were killed and their
dorsal skin was fixed in 3% buffered formaldehyde. To avoid irre-
levant variation of epidermal thickness, only samples obtained from
the same anatomical region of female mice of the same litter were
compared within each independent experiment. As sample locations
and the age of mice vary between the independent experiments, the
thicknesses of the epidermis cannot be compared between the figures.
Epidermal thickness was measured using the ImageJ software (NIH,
Bethesda, MD). Animal experimentation authorization number 1035/
3697/1-C was delivered to GK by the General Health Offices, Geneva.
siRNA knockdown
Keratinocytes were transfected in suspension by incubating 300,000–
600,000 cells in a solution containing 500ml of Opti-MEM, 3ml of
Lipofectamine RNAiMax (Invitrogen), and 20 pmol of a specific
siRNA (Invitrogen) according to the manufacturer’s protocols (Invitro-
gen). Two different human siOrai1 siRNAs (Invitrogen) were used
(sense strand siRNA): siOrai1 50-GGCGGAGUUUGCCCGCUUAtt-30
and siOrai1-2 50-CGUGCACAAUCUCAACUCGtt-30. Silencer select
negative control (4390843 Invitrogen) was used as control.
Cytosolic Ca2þ and Mn2þ quench measurements
Keratinocytes grown on coverslips were loaded for 30 minutes at room
temperature with the cell-permeant fluorescent Ca2þ indicator Fura-
2–acetoxymethyl (Biotium, Hayward, CA), washed twice, and kept for
10–15 minutes to allow de-esterification. Coverslips were inserted in a
thermostatic chamber, and experiments were conducted at 37 1C. Fura-
2–acetoxymethyl preparation was performed as previously described
(Arnaudeau et al., 2006; Darbellay et al., 2010). In brief, Fura-2–
acetoxymethyl was diluted in medium to a final concentration of 2mM
from a DMSO stock solution containing 1 mM Fura-2–acetoxymethyl,
100 mg ml 1 Pluronic F127 (Invitrogen), and 0.1% acetic acid.
Ratiometric images of Fura-2 fluorescence were monitored using a
 40 oil-immersion objective on an Axiovert microscope (S100 TV;
Carl Zeiss) equipped with a monochromator (Optoscan; Cairn
Research, Faversham, UK), which rapidly changed the excitation
wavelengths between 340 and 380 nm. Fluorescence emissions were
captured through a filter (510WB40; Omega Optical, Brattleboro, VT)
using a digital camera (CoolSnap HQ; Photometrics, Tucson, AZ).
Image acquisition and ratio analysis were performed using the
Metafluor software (6.3r7; Molecular Devices, Visitron Systems
GmbH, Puchheim, Germany). The maximal ratio was evaluated in
all conditions (using a solution containing 4mM ionomycin and 5 mM
Ca2þ ), ruling out any possible nonlinearity between data obtained in
keratinocytes transfected with different plasmids or siRNA. No
significant difference between the various maximal ratios was found.
Quench of Fura-2 fluorescence was measured at the excitation
wavelengths of 360 nm with Mn2þ (0.1 mM) in the extracellular
medium. All the images were background-corrected.
Statistical analysis
Bar graphs are shown as mean±SD, except for calcium measure-
ments, which are shown as mean±SEM. Sigmoidal fit was neither
forced through (0; 0) nor through (100; 100). Quantifications of KI67-
positive nuclei, Orai1 staining intensity, and cell counting were
performed in a blinded manner, as a motorized stage on the
microscope was used to automatically acquire 10 random fields in
each condition. Analyses to count the labeled nuclei, cell numbers,
and quantify Orai1 staining were carried out using the Metamorph
6.3r7 software (Molecular Devices). This method is used to follow cell
numbers over time in order to assess cellular proliferation. Images
were converted to grayscale images, inverted, and the same threshold
was applied to all images. For the quantification of Orai1 staining, the
epidermal variations of the staining intensity were normalized to the
dermal variations of the staining intensity. The staining was revealed
with 3,39-diaminobenzidine with identical time reaction in all
conditions. The time reaction was defined as the time necessary to
observe a gradient of staining between the basal and suprabasal layers
in the first coverslip of the control.
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